Schering Plough's Saphris Gets Strong Nod From FDA Panel
A safety profile showing less impact on weight and metabolic parameters than other atypical antipsychotics could set asenapine apart in crowded class if it is approved.
A safety profile showing less impact on weight and metabolic parameters than other atypical antipsychotics could set asenapine apart in crowded class if it is approved.